4D Molecular Therapeutics, Inc. FDMT 深 滬
等待開盤 08-21 09:30:00 美东时间
16.10
-0.660
-3.94%
華盛通- 最 高16.71
- 今 開16.50
- 成交量 163.08万股
- 最 低 15.63
- 昨 收 16.76
- 總市值 8.89亿
- 52周最高 16.93
- 市盈率 靜 --
- 換手率 2.95%
- 52周最低 5.97
- 委 比 96.39%
- 總股本 5524.42万
- 歷史最高 55.11
- 量 比 0.88
- 振 幅 6.44%
- 歷史最低 2.235
- 每 手 1
- 風險率 1.65%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股牛股 | 英伟达挑战者CBRS劲升15%，为OpenAI新模型提供算力；铠侠ADR升逾13%
受磷化铟抢货潮利好！半导体材料股AXT飙升17%；ARGX劲升16%，治疗自身免疫性肌炎药物临床试验积极；英伟达挑战者CBRS升逾15%，为OpenAI新模型提供算力>>
08-18 17:03
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics granted 35,200 RSUs to five new non-executive employees under its 2025 Employment Inducement Award Plan. The company is advancing therapies targeting blinding retinal diseases and cystic fibrosis, with its lead candidate, 4D-150, in Phase 3 development for wet age-related macular degeneration and diabetic macular edema. 4D-710 is the first genetic medicine to show successful CFTR transgene delivery in cystic fibrosis pat...
08-14 20:05
Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update
Vivani Medical reported Q2 2026 financial results and business progress, including successful enrollment and dosing of all participants in its SLIM-1™ Phase 1 trial for NPM-139, a semaglutide implant for chronic weight management. The company also entered into a non-exclusive agreement with Novo Nordisk to evaluate NPM-139 and its proprietary NanoPortal™ technology. Vivani announced the completion of its merger with ClearOne, creating Cortigent H...
08-13 20:05
美股大行评级 | 最高400美元！亚马逊绩后获11家大行上调目标价；苹果绩后评级分歧大！3家上调，3家下调；德康医疗、万事达、神经分泌生物科学获多家大行上调目标价
今日重点评级关注：TD Cowen：维持加拿大鹅"买入"评级，目标价从13美元升至18美元；瑞银：维持吉登运动服"买入"评级，目标价从110美元升至111美元
08-03 11:38
B. Riley Securities Initiates Coverage On 4D Molecular Therapeutics with Buy Rating, Announces Price Target of $37
B. Riley Securities analyst Mayank Mamtani initiates coverage on 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy rating and announces Price Target of $37.
07-31 23:52
美股大行评级 | 伯恩斯坦上调Robinhood目标价从130美元升至160美元；纽约梅隆银行、Datadog、五三银行、旅行者财产险集团获多家机构上调评级
今日重点评级关注：Needham：维持Immuneering"买入"评级，目标价从11美元升至18美元；富瑞：维持塞德斯医疗"买入"评级，目标价从90美元升至100美元
07-21 11:36
4D Molecular's One-Shot Eye Therapy Delivers Two-Year Win
On Saturday, 4D Molecular Therapeutics Inc. (NASDAQ:FDMT), a late-stage biotechnology firm focused on disease-targeted therapeutics, shared two-year results from its PRISM Phase 2b trial of 4D-150 in a broad wet age-related macular degeneration population. Key Efficacy Outcomes Through Two Years The...
07-20 21:05
4D Molecular Therapeutics Posts Strong 4D-150 Trial Results
4D Molecular Therapeutics ( ($FDMT) ) has provided an update. On July 18, 2026,...
07-20 20:58
4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population
4D-150在PRISM Phase 2b临床试验中展示了两年的积极数据，显示在治疗湿性黄斑变性（wet AMD）时，患者维持了最佳矫正视力和解剖结构控制，治疗负担显著降低（78%-87%），且耐受性良好，未见新安全问题。
07-18 19:15
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics granted 6 new non-executive employees 37,900 RSUs under the 2025 Employment Inducement Award Plan. The company is advancing therapies for blinding retinal diseases and cystic fibrosis, with lead product 4D-150 in Phase 3 for wet AMD and 4D-710 targeting CFTR gene delivery. Visit www.4DMT.com for more info.
07-17 20:05
